





# Retrospective Analysis of Patients with Synchronous Primary Breast and Thyroid Carcinoma

İlker Murat Arer<sup>1</sup> , Hakan Yabanoğlu<sup>1</sup> , Murat Kuş<sup>1</sup> , Aydıncan Akdur<sup>2</sup> , Tevfik Avcı<sup>2</sup> 

<sup>1</sup>Department of General Surgery, Baskent University, Adana Training and Research Center, Adana, Turkey

<sup>2</sup>Department of General Surgery, Baskent University School of Medicine, Ankara, Turkey

## ABSTRACT

**Objective:** Breast and thyroid cancers are commonly encountered malignancies. Increased risk of breast cancer in follow-up period of thyroid cancer or vice versa has been reported. However, they have some associations, synchronous presentation of these tumors is rare. We presented 12 patients diagnosed as breast and thyroid cancer and treated at the same time.

**Materials and Methods:** Mastectomy and thyroidectomy were performed in 19 patients at the same time. 7 patients were excluded because of benign thyroid pathology. Therefore 12 patients who had diagnosis of synchronous breast and thyroid cancer were included. Data regarding clinical, pathological, treatment and prognostic factors was retrospectively analyzed.

**Results:** Total thyroidectomy was performed in all patients. The mean age of patients was 54 years (min. 44- max. 70). Only one patient was male. Thyroid pathology was detected preoperatively by FDG PET-CT scan in 11 patients. Breast reconstruction was performed in three patients. The most commonly seen thyroid malignancy was papillary thyroid carcinoma. Postoperative complication rate was 33.3%. Adjuvant chemotherapy was given in 11 patients whereas one patient received adjuvant radiotherapy.

**Conclusion:** Although synchronous presentation of breast and thyroid cancer is rare, surgical treatment of both of these tumors can be safely performed at the same time. Association of these tumors should be evaluated by large scaled studies.

**Keywords:** Breast cancer, thyroid cancer, synchronous cancer, mastectomy, thyroidectomy

**Cite this article as:** Arer İM, Yabanoğlu H, Kuş M, Akdur A, Avcı T. Retrospective Analysis of Patients with Synchronous Primary Breast and Thyroid Carcinoma. Eur J Breast Health 2018; 14: 80-84.

## Introduction

Breast cancer is the most common cancer in women and it is the second most common cause of death among women due to cancer (1, 2). However, thyroid cancer is projected to be higher than lung, colorectal, and ovarian cancers in near future and estimated to be the third most common cancer of women in USA; it has not been a common cause of death due to cancer (3). 5-year survival rate of thyroid cancer ranges between 95-97% and 5-year survival rate of women with breast cancer is reported 81.9% therefore breast cancer is the determinant for survival in a patient with both breast and thyroid cancer (4, 5).

Both breast and thyroid cancers are frequent among women than men and they both have peak incidence in postmenopausal period (2). This finding, may be coincidence, has lead authors to investigate the association between breast and thyroid cancers. It is believed that they both have some interactions in hormonal and genetic level (6). Increased risk for second primary malignancies after diagnosis of thyroid carcinoma such as salivary gland, small intestine and adrenal gland has been found and this risk increases for breast cancer as the duration of the follow-up is prolonged (7). Although genetic factors, hormones and irradiation have been regarded as risk factors, no absolute relationship has been established yet between them. Either in breast cancer survivors, especially when HER-2 receptor was positive, or in thyroid cancer survivors, increased risk of the other cancer has been found (7, 8). This topic has been investigated by cohort and case-control studies in survivors but few studies presented patients diagnosed synchronously and treated at the same time (9, 10).

In this study, we present patients who were diagnosed preoperatively as synchronous breast cancer and thyroid pathology and underwent mastectomy and thyroidectomy at the same session.

## Materials and Methods

In total, 1297 thyroidectomies and 1210 mastectomies were performed between November 2011 and January 2016 at our institute. Data of patients were retrospectively collected via patient records. Among these patients, both mastectomy and thyroidectomy were performed in 19 patients. A total of 729 patients with diagnosis of thyroid cancer and 579 patients with diagnosis of breast cancer were found. 12 patients had diagnosis of synchronous breast and thyroid cancer, whereas 7 patients had breast cancer and benign thyroid disease.

Characteristics of patients, pathological characteristics of both cancers, neoadjuvant or adjuvant chemoradiotherapy status, postoperative radioiodine ablation therapy status, postoperative complications, recurrence, survival, disease-free survival and follow-up of the patients are given in Table 1 and 2. This study was conducted in accordance with the ethical standards of the responsible committee on human experimentation (institutional or regional) and with the Helsinki Declaration.

Statistical Packages for the Social Sciences (SPSS) software package was used for statistical analysis version 17.0 (SPSS Inc., Chicago, IL, USA). If continuous variables were normal, they were described as the mean±standard deviation ( $p>0.05$  in Kolmogorov-Smirnov test or

Shapiro-Wilk ( $n<30$ )), and if the continuous variables were not normal, they were described as the median.

## Results

A total of 12 mastectomies and thyroidectomies were performed simultaneously in patients with preoperative diagnosis of breast cancer and thyroid pathology. Mean age of patients was 54 years (min. 44-max. 70). Only 1 (8.3%) patient was male. Half of the patients had preoperative thyroid fine needle aspiration with diagnosis of 3 malignant cytology, 2 Hurthle cell neoplasia and 1 follicular neoplasia. Other 6 patients had either hyperthyroidism or thyroid nodule larger than 3 cm. on physical examination and ultrasound.

11 (91.7%) patients had preoperative FDG PET-CT scan and thyroid pathology was detected in all of them. In all 12 patients, primary complaint of the patient was lump or swelling in the breast therefore none of the patients presented with primary thyroid pathology. Thyroid pathology was detected on FDG PET-CT scan or physical examination. Total thyroidectomy was performed in all patients. Only 1 (8.3%) patient had papillary thyroid lymph node metastasis in the follow-up period and modified radical lymph node dissection was performed. (Table 3) shows the details of breast surgeries performed in all cases. Immediate breast reconstruction type was silicone implantation and

Table 1. Characteristics of patients according to breast pathology

Patient no.	Age	Sex	Operation	BC histology	BC TNM#	ER/PR**	Neoadjuvant therapy	Adjuvant therapy
1	53	F	SM+ALND+TT	Invasive DC+DCIS	T2N1M0	60-70/5	None	AC+DT+Tamoxifen RT (66Gy)
2	50	F	MRM+IBR+TT	Invasive LC+DCIS	T2N2M0	60-70/60-70	None	AC+DT+TzM RT(50Gy)
3	49	F	SM+SLND+IBR+TT	Invasive DC+DCIS	T1cN0M0	Neg/Neg	None	Unknown regimen*
4	48	F	MRM+TT	Invasive BC	TXN2M0/T0N0M0	95/70	AC+DT+TzM	TzM RT (50Gy)
5	44	F	SM+SLND+TT	Invasive DC+DCIS	T1cN0M0	85/95	None	AC+Tamoxifen
6	63	F	MRM+TT	Invasive DC+DCIS	T2N1aM0	Neg/Neg	None	AC+TzM+ Tamoxifen
7	53	M	SiM+SLND+TT	Invasive DC+DCIS	T1cN0M0	90-95/30-40	None	Unknown regimen*
8	50	F	MRM+TT	Mixed carcinoma+DCIS	T2N3aM0	100/70	None	AC+DT RT(50Gy)
9	53	F	SM+SLND+TT	Invasive DC	T2N1M0	Neg/Neg	None	CEF+DT RT(50.4Gy)
10	70	F	MRM+TT	Invasive DC+DCIS	T2N2aM0	90-95/15-20	None	CEF+DT RT (50.4Gy)
11	62	F	SM+SLND+TT	Invasive DC+DCIS	T1cN0M0	90-95/10-15	None	RT (50.4Gy)
12	53	F	MRM+DBRi+TT	Invasive DC+DCIS	T2N3M0	Neg/Neg	None	CEF+DT+TzM RT(50Gy)

\*: Adjuvant chemoradiotherapy given in another hospital.

\*\* : Estrogen or progesterone receptor percentage.

# : Preoperative clinical and postoperative pathological TNM stage (Clinical TNM stage before neoadjuvant therapy and postoperative pathological TNM stage was both given for patient number 4)

AC: adriamycin+cyclophosphamide; ALND: axillary lymph node dissection; BC: breast cancer; CEF: Cyclophosphamide+Epirubicin+Flourouracil; DBRi: delayed breast reconstruction with implantation; DC: ductal carcinoma; DCIS: ductal carcinoma insitu; DT: docetaxel; ER: estrogen receptor; F: female; IBR: immediate breast reconstruction; LC: lobular carcinoma; M: male, MRM: modified radical mastectomy; PR: progesterone receptor; SM: simple mastectomy; SLND: sentinel lymph node dissection; SM: segmental mastectomy; RT: radiotherapy; TT: total thyroidectomy; TzM: trastuzumab

Table 2. Characteristics of patients according to thyroid cancer, survival and complications

Patient no.	Age	Sex	TC histology	TC size (mm)	RIA (mci)	Disease free survival (Months)	Follow-up (Months)	Postoperative Complication
1	53	F	PC	20	150	29	32	Re-excision (Breast)
2	50	F	PC	15	None	22	22	SSI
3	49	F	PC	6	UR	12	12	None
4	48	F	PC	8	None	22	22	None
5	44	F	PC	17	100	14	14	None
6	63	F	PC	7	None	30	30	None
7	53	M	PC	6	UR	9	9	None
8	50	F	PC	2	None	12	12	Seroma
9	53	F	FC	20	100	8	8	None
10	70	F	PC	2	None	8	8	None
11	62	F	PC	1	None	4	4	None
12	53	F	PC	30	100	15	15	None

FC: follicular carcinoma; F: female, M: male; PC: papillary carcinoma; RIA: radioactive iodine ablation; SSI: surgical site infection; TC: thyroid cancer; UR: unknown regimen

Table 3. Breast surgery type which was performed for patients

Surgery type	Number of patients
MRM	4
SM+sLND	4
SM+aLND	1
SM+aLND+IBR	1
Simple mastectomy+sLND	1
MRM+IBR	1
MRM+DBR	1

aLND: axillary lymph node dissection; DBR: delayed breast reconstruction; IBR: immediate breast reconstruction; MRM: modified radical mastectomy; sLND: sentinel lymph node dissection; SM: segmental mastectomy

delayed breast reconstruction type was tissue expander and silicone implant.

Only 1 (8.3%) patient who underwent simple mastectomy (SM) with axillary lymph node dissection (LND) had positive surgical margins and reoperation with wide surgical resection was performed for this patient.

**Histopathological findings**

8 (66.8%) invasive ductal breast carcinoma + ductal carcinoma in situ and papillary thyroid carcinoma, 1 (8.3%) invasive lobular breast carcinoma + ductal carcinoma in situ and papillary thyroid carcinoma, 1 (8.3%) invasive breast carcinoma and papillary thyroid carcinoma, 1 (8.3%) mixed (invasive ductal and invasive mucinous) breast carcinoma + ductal carcinoma in situ and papillary thyroid carcinoma

and 1 (8.3%) invasive ductal breast carcinoma and follicular thyroid carcinoma.

**Treatment details**

8 (66.8%) patients received adjuvant chemotherapy and radiotherapy, 1 (8.3%) patient received neoadjuvant and adjuvant chemotherapy and radiotherapy, 2 (16.6%) patients received adjuvant chemotherapy only and 1 (8.3%) patient received radiotherapy only. Only half of the patients (50%) received radioiodine ablation therapy.

**Postoperative complications**

Postoperative complications were due to mastectomy. The overall complication rate was 16.7%. These complications were seroma in 1 patient and wound infection in 1 patient, who were treated by conservative management. Average disease-free survival was 15.4 months (range between 4-30 months). Mean follow-up was 15.6 months (range between 4-32 months). No mortality was observed in the follow-up period.

**Discussion and Conclusion**

Breast cancer is the most common malignancy in women around the world. The 5-year relative survival rate of this cancer improved recently due to early detection and advances in treatment (11). As survival rates and incidence of this cancer has increased, the number of breast cancer survivors has also increased. During the diagnosis of breast cancer patients, detection of second primary malignancy is a significant issue.

Warren et al. (12) described synchronous primary cancers as a tumor diagnosed simultaneously with breast cancer or within a time interval of 6 months. The most common synchronous malignancy of breast cancer is thyroid cancer or vice versa (9, 13). There is an increased risk of secondary malignancy for breast or thyroid cancer survivors (14). Many studies have suggested that there is an association between thyroid diseases and breast carcinoma (15) whereas some authors did not find any obvious association (16).

The interactions between thyroid and breast disorders are based on hormonal and cellular receptor mechanisms (17, 18). In a recent prospective study, although no statistical difference was observed, thyroglobulin gene polymorphism and autoimmune thyroid disease was found to have high prevalence among breast cancer patients (19). Thyroid cancer survivors also have been found to develop breast cancer early, have more estrogen and progesterone receptor positive tumors, and have a greater incidence of mixed invasive cancer (20). Estrogen receptors have been found in thyroid tissue (21). Estrogen was found to have an influence on thyroid glands (22). The histology of the breast cancer that develops after thyroid cancer is different than the general population, with a greater percentage of mixed ductal and lobular invasive cancer and a greater percentage of ER/PR-positive tumors (20). In this current study, we found high percentage of ER/PR positive tumors (66.6%). Although indicated by many studies, an association between breast and thyroid cancer still remains controversial. All these studies suggest a possible interaction among breast and thyroid cancers.

The first malignancy diagnosed in our patients was breast cancer. Thyroid pathology was diagnosed either on physical examination or preoperative evaluation of breast cancer with FDG PET-CT scan. FDG PET-CT scan has been widely used for the diagnosis, initial staging, restaging, early treatment response assessment and evaluation of metastatic disease response of breast cancer (23). Although it has some disadvantages like irradiation, it is useful for detecting metastasis of breast cancer. It is reported to have a negative predictive value of 90 % for detection of thyroid nodules (24). It also detected 91.7 % of patients with thyroid pathology in our study.

Thyroid hormones have been found to stimulate cell proliferation in breast tissue, enhance the estradiol-mediated effects on cell proliferation, promote growth and induce the expression of progesterone receptors by mimicking the effects of estradiol (25, 26). Thyroid receptors found to be located in both normal and malignant breast cells (27). In a recent study, high free T4 levels and thyroid peroxidase antibody (TPO-Ab) levels were found to be associated with an increased risk of breast cancer (28). In a meta-analysis including 8 cross-sectional studies, authors found serum levels of free T3, TPO-Ab and thyroglobulin antibody to be significantly higher in patients with breast cancer than in healthy controls (29). Therefore, there is great evidence that the breast and thyroid tissue has some interactions on hormonal basis mainly influenced by the hormones secreted from thyroid gland. Thyroid receptors (TR) are encoded by two genes, TR $\alpha$  and TR $\beta$ , which are located on human chromosomes 17 and 3, respectively. In a recent study performed among Chinese people, aberrant expression and mutations of the TR $\beta$ 1 gene were found to be associated with the development of breast cancer (30). Thus, thyroid hormone receptors play a role in breast cancer development.

Although the most common thyroid cancer type found to be associated with breast cancer is papillary thyroid cancer (85.9%), follicular cancer (11%) is also found to be increased in frequency (20). In our study, papillary thyroid cancer (91.7%) is also found to be the most common histologic type together with breast cancer whereas follicular cancer incidence was found as 8.3%.

In this current study we performed both mastectomy and thyroidectomy at the same time. Although our study has a limitation with short follow-up period, the main determinant of patients with synchronous breast and thyroid cancer is the breast cancer because of shorter sur-

vival rates. Performing mastectomy first and then thyroidectomy in the follow-up period may result in delay of the chemotherapy and radiotherapy. We believe that these two operations can be safely performed simultaneously as thyroidectomy adds only 60 minutes to the overall operation time, so it does not increase the risk for perioperative or postoperative complications due to anesthesia. Adjuvant radiotherapy for breast cancer reported to have some influence on thyroid tissue leading to hypothyroidism (31). Radiation is also known to increase risk for thyroid malignancy. Thus, it is better to diagnose thyroid pathology before breast cancer treatment and preoperative assessment of thyroid gland in patients diagnosed with breast cancer is crucial.

These different findings from literature represents one of the limitation of our study which was the result of small patient population. Retrospective design of this study is another limitation.

Although the exact mechanism of association between breast and thyroid cancers still remains unknown, synchronous presentation of these tumors can be seen. Thus, preoperative assessment of thyroid gland by physical examination is mandatory in patients diagnosed with breast cancer and if these patients are clinically negative for thyroid pathology radiological evaluation can be performed for them. Treatment for both of these cancers can be safely performed at the same time.

**Ethics Committee Approval:** Ethics committee approval was not taken due to retrospective design of the study.

**Informed Consent:** Informed consent was not taken due to retrospective design of the study.

**Peer-review:** Externally peer-reviewed.

**Author Contributions:** Concept - İ.M.A., H.Y.; Design - İ.M.A., H.Y.; Supervision - H.Y.; Resources - M.K., T.A.; Materials - A.A., T.A.; Data Collection and/or Processing - A.A., M.K.; Analysis and/or Interpretation - İ.M.A., M.K.; Literature Search - M.K., T.A.; Writing Manuscript - İ.M.A., H.Y.; Critical Review - H.Y., A.A.; Other - T.A.

**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** The authors declared that this study has received no financial support.

## References

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. *CA Cancer J Clin* 2015; 65: 87-108. (PMID: 25651787) [[CrossRef](#)]
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. *CA Cancer J Clin* 2015; 65: 5-29. (PMID: 25559415) [[CrossRef](#)]
3. Aschebrook-Kilfoy B, Kaplan EL, Chiu BC, Angelos P, Grogan RH. The acceleration in papillary thyroid cancer incidence rates is similar among racial and ethnic groups in the United States. *Ann Surg Oncol* 2013; 20: 2746-2753. (PMID: 23504142) [[CrossRef](#)]
4. Garner CN, Ganetzky R, Brainard J, Hammel JP, Berber E, Siperstein AE, Milas M. Increased prevalence of breast cancer among patients with thyroid and parathyroid disease. *Surgery* 2007; 142: 806-813; discussion 813.e1-3. (PMID: 18063060)
5. De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, Trama A, Visser O, Brenner H, Ardanaz E, Bielska-Lasota M, Engholm G, Nennecke A, Siesling S, Berrino F, Capocaccia R; EUROCARE-5 Working Group. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE: 5-a population-based study. *Lancet Oncol* 2014; 15: 23-34. (PMID: 24314615) [[CrossRef](#)]

6. Hardefeldt PJ, Eslick GD, Edirimanne S. Benign thyroid disease is associated with breast cancer: a meta-analysis. *Breast Cancer Res Treat* 2012; 133: 1169-1177. (PMID: 22434524) [\[CrossRef\]](#)
7. Sandeep TC, Strachan MW, Reynolds RM, Brewster DH, Scélo G, Pukkala E, Hemminki K, Anderson A, Tracey E, Friis S, McBride ML, Kee-Seng C, Pompe-Kirn V, Kliever EV, Tonita JM, Jonasson JG, Martos C, Boffetta P, Brennan P. Second primary cancers in thyroid cancer patients: a multinational record linkage study. *J Clin Endocrinol Metab* 2006; 91: 1819-1825. (PMID: 16478820) [\[CrossRef\]](#)
8. Marcheselli R, Marcheselli L, Cortesi L, Bari A, Cirilli C, Pozzi S, Ferri P, Napolitano M, Federico M, Sacchi S. Risk of Second Primary Malignancy in Breast Cancer Survivors: A Nested Population-Based Case-Control Study. *J Breast Cancer* 2015; 18: 378-385. (PMID: 26770245) [\[CrossRef\]](#)
9. Lee J, Park S, Kim S, Kim J, Ryu J, Park HS, Kim SI, Park BW. Characteristics and Survival of Breast Cancer Patients with Multiple Synchronous or Metachronous Primary Cancers. *Yonsei Med J* 2015; 56: 1213-1220. (PMID: 26256962) [\[CrossRef\]](#)
10. Zhang L, Wu Y, Liu F, Fu L, Tong Z. Characteristics and survival of patients with metachronous or synchronous double primary malignancies: breast and thyroid cancer. *Oncotarget* 2016; 7: 52450-52459. (PMID: 27223440) [\[CrossRef\]](#)
11. DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. *CA Cancer J Clin* 2014; 64: 52-62. (PMID: 24114568) [\[CrossRef\]](#)
12. Warren S, Gates O. Multiple primary malignant tumors: a survey of the literature and a statistical study. *Am J Cancer* 1932; 16: 1358-1414.
13. Nio Y, Iguchi C, Itakura M, Toga T, Hashimoto K, Koike M, Omori H, Sato Y, Endo S. High Incidence of Synchronous or Metachronous Breast Cancer in Patients with Malignant and Benign Thyroid Tumor or Tumor-like Disorders. *Anticancer Res* 2009; 29: 1607-1610. (PMID: 19443373)
14. Ron E, Curtis R, Hoffman DA, Flannery JT. Multiple primary breast and thyroid cancer. *Br J Cancer* 1984; 49: 87-92. (PMID: 6691901) [\[CrossRef\]](#)
15. Turken O, NarIn Y, DemIrbas S, Onde ME, Sayan O, KandemIr EG, YaylaçI M, Ozturk A. Breast cancer in association with thyroid disorders. *Breast Cancer Res* 2003; 5: R110-R113. (PMID: 12927040) [\[CrossRef\]](#)
16. Simon MS, Tang MT, Bernstein L, Norman SA, Weiss L, Burkman RT, et Simon MS, Tang MT, Bernstein L, Norman SA, Weiss L, Burkman RT, Daling JR, Deapen D, Folger SG, Malone K, Marchbanks PA, McDonald JA, Strom BL, Wilson HG, Spirtas R. Do thyroid disorders increase the risk of breast cancer? *Cancer Epidemiol Biomarkers Prev* 2002; 11: 1574-1578. (PMID: 12496046)
17. Giani C, Fierabracci P, Bonacci R, Gigliotti A, Campani D, De Negri F, Cecchetti D, Martino E, Pinchera A. Relationship between breast cancer and thyroid disease: relevance of autoimmune thyroid disorders in breast malignancy. *J Clin Endocrinol Metab* 1996; 81: 990-994. (PMID: 8772562) [\[CrossRef\]](#)
18. Davies TF. The thyrotrophin receptors spread themselves around. *J Clin Endocrinol Metabol* 1994; 79: 1232-1233. (PMID: 7962313) [\[CrossRef\]](#)
19. Ozmen T, Akkiprik M, Kaya H, Gulluoglu BM. Breast Cancer and Autoimmune Thyroid Disease Relationship: Can Hormonal Factors or Thyroglobulin Gene Polymorphism Be the Common Factor? *J Breast Health* 2014; 10: 35-41. [\[CrossRef\]](#)
20. Kuo JH, Chabot JA, Lee JA. Breast cancer in thyroid cancer survivors: An analysis of the Surveillance, Epidemiology, and End Results-9 database. *Surgery* 2016; 159: 23-29. (PMID: 26522696) [\[CrossRef\]](#)
21. Bhatia S, Sklar C. Second cancers in survivors of childhood cancer. *Nat Rev Cancer* 2002; 2: 124-132. (PMID: 12635175) [\[CrossRef\]](#)
22. Kawabata W, Suzuki T, Moriya T, Fujimori K, Naganuma H, Inoue S, Kinouchi Y, Kameyama K, Takami H, Shimosegawa T, Sasano H. Estrogen Receptors (alpha and beta) and 17, beta-hydroxysteroid dehydrogenase type 1 and 2 in Thyroid Disorders: Possible in situ estrogen synthesis and actions. *Mod Pathol* 2003; 16: 437-444. (PMID: 12748250) [\[CrossRef\]](#)
23. Kitajima K, Miyoshi Y. Present and future role of FDG-PET/CT imaging in the management of breast cancer. *Jpn J Radiol* 2016; 34: 167-180. (PMID: 26733340) [\[CrossRef\]](#)
24. Sager S, Vatankulu B, Erdogan E, Mut S, Teksoz S, Ozturk T, Sonmezoglu K, Kanmaz B. Comparison of F-18 FDG-PET/CT and Tc-99m MIBI in the preoperative evaluation of cold thyroid nodules in the same patient group. *Endocrine* 2015; 50: 138-145. (PMID: 25795290) [\[CrossRef\]](#)
25. Hall LC, Salazar EP, Kane SR, Liu N. Effects of thyroid hormones on human breast cancer cell proliferation. *J Steroid Biochem Mol Biol* 2008; 109: 57-66. (PMID: 18328691) [\[CrossRef\]](#)
26. Shao ZM, Sheikh MS, Rishi AK, Dawson MI, Li XS, Wilber JF, Feng P, Fontana JA. Thyroid hormone enhancement of estradiol stimulation of breast carcinoma proliferation. *Exp Cell Res* 1995; 218: 1-8. (PMID: 7737350) [\[CrossRef\]](#)
27. Conde I, Paniagua R, Zamora J, Blázquez MJ, Fraile B, Ruiz A, Arenas MI. Influence of thyroid hormone receptors on breast cancer cell proliferation. *Ann Oncol* 2006; 17: 60-64. (PMID: 16282247) [\[CrossRef\]](#)
28. Brandt J, Borgquist S, Manjer J. Prospectively measured thyroid hormones and thyroid peroxidase antibodies in relation to risk of different breast cancer subgroups: a Malmö Diet and Cancer Study. *Cancer Causes Control* 2015; 26: 1093-1104. (PMID: 26033776) [\[CrossRef\]](#)
29. Shi XZ, Jin X, Xu P, Shen HM. Relationship between breast cancer and levels of serum thyroid hormones and antibodies: a meta-analysis. *Asian Pac J Cancer Prev* 2014; 15: 6643-6647. (PMID: 25169502) [\[CrossRef\]](#)
30. Ling Y, Ling X, Fan L, Wang Y, Li Q. Mutation analysis underlying the downregulation of the thyroid hormone receptor  $\beta$ 1 gene in the Chinese breast cancer population. *Onco Targets Ther* 2015; 8: 2967-2972. (PMID: 26527882)
31. Johansen S, Reinertsen KV, Knutstad K, Olsen DR, Fosså SD. Dose distribution in the thyroid gland following radiation therapy of breast cancer--a retrospective study. *Radiat Oncol* 2011; 6: 68. (PMID: 21651829) [\[CrossRef\]](#)